Table SI. *Inclusion and exclusion criteria*

Inclusion criteria
Chronic plaque psoriasis
Prospective or retrospective
Thirty participants or more
Daily practice, database, registries, "real-world", "real-life", observational, cohort
Patients aged ≥ 18 years
English, Dutch or German language
Article reports on one of the following effectiveness outcomes: PASI, PhGA on a scale of 0–5, 0–6 or 0–7 or BSA
Reporting on the effectiveness of following treatments: adalimumab, etanercept, infliximab, ustekinumab, acitretin, fumarates, cyclosporine, or methotrexate
Reporting data analysed with the as-treated approach (per protocol analysis)
Exclusion criteria
Case reports
RCTs or clinical trials
Safety studies
In vitro studies and other laboratory studies
Pharmacokinetic studies
Cost-effectiveness studies
Open-label studies with a stringent protocol not reflecting daily practice
Studies not reporting the time point at which effectiveness was measured
Studies not reporting the dosage of treatment
Studies not reporting data separately per treatment
Studies reporting solely on non-systemic treatments such as phototherapy and topical therapies
Studies reporting solely on alefacept or efalizumab since these agents are no longer available for psoriasis treatment
Articles reporting on a combination of plaque psoriasis with other subtypes of psoriasis when the effectiveness data solely on chronic plaque psoriasis could not be extracted from the article
Studies describing only outcomes on psoriatic arthritis
Studies on specific psoriasis patient populations (e.g. psoriasis patients with HIV or hepatitis)
Studies in which conventional systemic agents were combined with other conventional systemic therapies
In patient cohorts treated with biologics, combination with conventional systemic was not excluded but described when appropriate

RCT: randomized controlled trial; PASI: Psoriasis Area and Severity Index; PhGA: Physician's Global Assessment; BSA: body surface area.

Table SII. *Search strategy*

Search strategy for PubMed and EMBASE:
Words that indicated daily practice and effectiveness:
"registry"; "database"; "daily practice"; "clinical practice"; "real-world"; "real-life"; "treatment outcome"; "observational"; "prospective"; "retrospective"; "PASI"; "PGA"; "BSA"
Combined with the treatments of interest:
"drug therapy"; "drug effects"; "therapeutic use"; "dermatologic agents"; "biological agents"; "tumour necrosis factor-alpha antagonists"; "anti-TNF"; "TNF-alpha inhibitors"; "antibodies monoclonal"; "antibodies monoclonal humanized"; "monoclonal antibody CA2"; "TNFR-Fc fusion protein"; "methotrexate"; "cyclosporine"; "acitretin"; "fumaric acid esters"; "fumarates"; "etanercept"; "adalimumab"; "infliximab"; "ustekinumab"

TNF: tumour necrosis factor; TNFR-Fc: tumour necrosis factor receptor (p75) Fc fusion protein; PASI: Psoriasis Area and Severity Index; PhGA: Physician's Global Assessment; BSA: body surface area.

Table SIII. *Evidence table*

First author (Ref), year	Design	Dosage	Outcome measures	Date of evaluation (licensed dose)	Results (mean)
Adalimumab					
Ryan (12), 2009 (*n*=39[a])	Retrosp	Adalimumab 80 mg (W 0) followed by 40 mg once W (from W1) SC or adalimumab 40 mg EOW (from W1) SC. According to the response the dose interval was increased or decreased.	PASI75	W 16	PASI75: 38%
			Monotherapy	W 24	PASI75: 62%
				W 48	PASI75: 69%
				W 72	PASI75: 71%
			PASI75 combination therapy	W 16	PASI75: 56%
				W24	PASI75: 50%
				W48	PASI75: 80%
				W72	PASI75: 67%
van Lümig (13), 2010 (*n*=30[a])	Prosp.[b]	Adalimumab 80 mg (W0) followed by 40 mg EOW (from W1–12) SC. From W12–48, according to the response the dose interval was maintained, increased or decreased. (Adalimumab 40 mg EOW or 40 mg every 10 days or 40 mg once W.	PASI50	W 12	PASI50: 70%
			PASI75	Comparing with original	PASI75: 27%
			PASI90	PASI (licensed dose)	PASI90: 10%
				W 24	PASI50: 61%
				Comparing with original	PASI75: 36%
				PASI	PASI90: 7%
				W 48	PASI50: 77%
				Comparing with original	PASI75: 54%
				PASI	PASI90: 15%
				W 12	PASI50: 30%
				Comparing with course	PASI75: 13%
				PASI (licensed dose)	PASI90: 13%
				W 24	PASI50: 50%
				Comparing with course	PASI75: 7%
				PASI	PASI90: 0%
				W 48	PASI50: 54%
				Comparing with course	PASI75: 23%
				PASI	PASI90: 15%
Warren (14), 2010 (*n*=46[a])	Retrosp.	Adalimumab 80 mg (W 0) followed by 40 mg EOW (from W1) SC. According to the response the dose was increased to 40 mg weekly the first 4 months.	PASI50	W 16	PASI50: 84%
			PASI75	(licensed dose)	PASI75: 64%
			PASI90		PASI90: 36%
				W 24	PASI50: 77%
					PASI75: 65%
					PASI90: 42%
				W 52	PASI50: 56%
					PASI75: 48%
					PASI90: 41%
Fotiadou (15), 2012 (*n*=52[a])	Retrosp.	Adalimumab 80 mg (W 0) followed by 40 mg EOW (from W1) SC. According to the response the dose interval was increased or decreased	PASI50	W 16	PASI50: 90%
			PASI75		PASI75: 68%
			PASI90		PASI90: 42%
				W 24	PASI50: 95%
					PASI75: 82%
					PASI90: 56%
				W 52	PASI75: 89%
					PASI90: 75%
				W 72	PASI50: 100%
					PASI75: 88%
					PASI90: 75%
López-Ferrer (16), 2013 (*n*=119[a])	Retrosp.	Adalimumab 80 mg (W 0) followed by 40 mg EOW (From W1) SC.	PASI75	W 16	PASI75: 64%
			PASI90		PASI90: 49%
				W 24	PASI75: 67%
					PASI90: 60%
				W 52	PASI75: 76%
					PASI90: 70%
				W 104	PASI75: 83%
					PASI90: 71%
van Lümig (17), 2013 (*n*=85[a])	Prosp.	Adalimumab 80 mg (W 0) followed by 40 mg EOW (from W1) SC. According to the response the dose interval was decreased.	PASI50	W 12	PASI50: 65%
			PASI75	Comparing with original	PASI75: 35%
			PASI90	PASI	PASI90: 11%
			PASI100		PASI100: 0%
				W 24	PASI50: 69%
				Comparing with original	PASI75: 45%
				PASI	PASI90: 17%
					PASI100: 6%

				W 48	PASI50: 83%
				Comparing with original	PASI75: 57%
				PASI	PASI90: 21%
					PASI100: 4%
				W 96	PASI50: 94%
				Comparing with original	PASI75: 44%
				PASI	PASI90: 22%
					PASI100: 0%
				W 132	PASI50: 83%
				Comparing with original	PASI75: 50%
				PASI	PASI90: 0%
					PASI100: 0%
				W 12	PASI50: 46%
				Comparing with course	PASI75: 27%
				PASI	PASI90: 8%
					PASI100: 0%
				W 24	PASI50: 56%
				Comparing with course	PASI75: 31%
				PASI	PASI90: 11%
					PASI100: 6%
				W 48	PASI50: 72%
				Comparing with course	PASI75: 38%
				PASI	PASI90: 15%
					PASI100: 4%
				W 96	PASI50: 72%
				Comparing with course	PASI75: 44%
				PASI	PASI90: 22%
					PASI100: 0%
				W 132	PASI50: 50%
				Comparing with course	PASI75: 50%
				PASI	PASI90: 0%
					PASI100: 0%
Menting (18), 2014	Prosp.	Adalimumab 80 mg (W 0) followed by 40 mg	PASI75	W 12	PASI75: 54%
(*n*=90 TE[a])		EOW (from W1) SC or 40 mg every 10 days or	PASI90 Naive		PASI90: 42.9%
		40 mg once W.		W 52	PASI90: 43.5%
			PASI75	W 12	PASI75: 26%
			PASI90		PASI90: 18%
			Non-naive	W 52	PASI90: 8%
Etanercept					
de Groot (19), 2006	Retrosp.	Etanercept 50 mg BIW SC (W0–12) .	PASI50	W 12	PASI50: 71%
(*n*=50[a])			PASI75	(licensed dose)	PASI75: 22.6%
			PASI90		PASI90: 6.5%
			MPD		MPD: 57.5%
			MBSAD		MBSAD: 62.3%
		Etanercept 25 mg BIW SC (W0–12).	PASI50	W 12	PASI50: 85.7%
			PASI75		PASI75: 21.4%
			PASI90		PASI90: 7.1%
			MPD		MPD: 60%
			MBSAD		MBSAD: 54.1%
Berends (20), 2007	Prosp.	Etanercept 50 mg BIW SC (W0–12) followed	PASI50	W 12 (licensed dose)	PASI50: 82%
(*n*=45[a])		by 25 mg BIW (W12–24).	PASI75		PASI75: 39%
				W 18 (licensed dose)	PASI50: 88%
					PASI75: 47%
				W 24 (licensed dose)	PASI50: 71%
					PASI75: 50%
		25 mg BIW SC (W0–24).	PASI50	W 12	PASI50: 71%
			PASI75		PASI75: 24%
				W 18	PASI50: 79%
					PASI75: 64%
				W 24	PASI50: 79%
					PASI75: 57%
Barrera (21), 2008	Retrosp.	Etanercept 50 mg BIW SC (W0 – 12) followed	PASI50	Cycle 1	PASI50: 65.5%
(*n*=66)		by 25 mg BIW (W12–24) or 25 mg BIW	PASI75	W 12 (licensed dose)	PASI75: 36.1%
		(W0–24). Thereafter one of these treatments by	PASI90		PASI90: 21.3%
		losing 50% of the PASI. Three cycles of 24W.	MPD		
				Cycle 1	PASI50: 91.3%
				W 24	PASI75: 76.1%
					PASI90: 41.3%
					MPD: 78.1%

				Cycle 2	PASI50: 72.4%
				W 12	PASI75: 31%
					PASI90: 10.3%
				Cycle 2	PASI50: 94.7%
				W 24	PASI75: 63.2%
					PASI90: 31.6%
					MPD: 66.9%%
				Cycle 3	PASI50: 60%
				W 12	PASI75: 33.3%
					PASI90: 20%
				Cycle 3	PASI50: 85.7%
				W 24	PASI75: 42.9%
					PASI90: 28.6%
					MPD: 76%
Driessen (22), 2008 ($n=80$[a])	Prosp.	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–24). According to the response the dose of 25 mg BIW was temporary increased.	PASI50 PASI75 PASI90 MPD	W 12 (licensed dose) W 24 (licensed dose)	PASI50: 66% PASI75: 20% PASI90: 8% MPD: 59%
		Etanercept 25 mg BIW SC (W0–24). According to the response the dose was temporary increased.	PASI50 PASI75 PASI90 MPD	W 12 W 24	PASI50: 68% PASI75: 21% PASI90: 5% MPD: 60%
Gisondi (40), 2008 ($n=58$)	Retrosp.	Etanercept 25 mg BIW SC.	MPD	W 24	MPD: 74.5%
Antoniou (23), 2009 ($n=77$[a])	Retrosp.	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–48). According to the response the dose was increased to 50 mg BIW.	PASI50 PASI75	W 24 W 48 	PASI50: 79% PASI75: 53% PASI50: 81% PASI75: 49%
Driessen (24), 2009 ($n=90$[a])	Prosp.	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–24) or Etanercept 25 mg BIW SC (W0–W24). According to the response the dose was temporary increased to 50 mg BIW.	PASI50 PASI75 PASI90 MPD	W 24	PASI50: 69% PASI75: 39% PASI90: 18% MPD: 59.7%
Jiménez-Puya (25), 2009 ($n=58$)	Retrosp.	Etanercept 50 mg BIW SC or 25 mg BIW SC.	PASI50 PASI75 PASI90 MBSAD	W 8 W 16	PASI50: 77.6% PASI75: 41.4% PASI90: 6.9% PASI50: 86.8%
					PASI75: 66%
					PASI90: 37.7%
				W 24	PASI50: 97.5%
					PASI75: 85%
					PASI90: 57.5%
				W 32	PASI50: 100%
					PASI75: 80.8%
					PASI90: 57.7%
				W 40	PASI50: 94.7%
					PASI75: 84.2%
					PASI90: 52.6%
				48W	PASI50: 100%
					PASI75: 92.3%
					PASI90: 69.2%
					MBSAD: 85%
Mazzotta (26), 2009 ($n=234$)	Prosp.[c]	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–24)	PASI50 PASI75 MPD (psoriasis)	W 12 (licensed dose) W 24 (licensed dose)	PASI50: 77.9% PASI75: 41% MPD: 67.7% PASI50: 85.7%
					PASI75: 73.2%
					MPD: 81%
			PASI50 PASI75 MPD (psoriasis + psoriatic arthritis)	W 12 (licensed dose) W 24 (licensed dose)	PASI50: 64 % PASI75: 43% MPD: 66.7% PASI50: 79.8%
					PASI75: 61.8%
					MPD: 80.5%
Warren (27), 2009 ($n=70$[a])	Retrosp.	Etanercept 25 mg BIW SC. According to the response the dose was increased to 50 mg BIW.	PASI50 PASI75 PASI90 MPD	W 12	PASI50: 67% PASI75: 35% PASI90: 7% MPD: 55%

				W 24	PASI50: 67% PASI75: 41% PASI90: 6% MPD: 59%
Antoniou (28), 2010 ($n=35$[a])	Retrosp.[d]	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–24).	PASI75	W 24 (licensed dose)	PASI75: 57%
van Lümig (13), 2010 ($n=30$[a])	Prosp.	Etanercept 50 mg BIW SC or 25 mg BIW SC (W0 – 12). Thereafter dosage according to physician.	PASI50 PASI75 PASI90	W 12	PASI50: 60% PASI75: 13% PASI90: 3.3%
				W 24	PASI50: 58% PASI75: 19% PASI90: 3.3%
				W 48	PASI50: 79% PASI75: 25%
Zaragoza (29), 2010 ($n=43$)	Retrosp.[c]	Etanercept 50 mg BIW SC (W0–12) or 25 mg BIW SC (W0–12) followed by 25 mg BIW SC (W12–24). According to the response the dose was increased or decreased.	PASI50 PASI75 MPD	W 24	PASI50: 81.4% PASI75: 60.5% MPD: 73.8%
				W 48	PASI50: 90.5% PASI75: 71.4% MPD: 79.6%
				W 72	MPD: 81.3%
				W 96	MPD: 38.2%
				W 120	MPD: 87.6%
				W 144	MPD: 88.4%
Antoniou (30), 2011 ($n=118$[a])	Retrosp.	Etanercept 50 mg BIW SC (W0–12) followed by 50 mg once W (from W 12).	PASI50 PASI75	W 12 (licensed dose)	PASI50: 59% PASI75: 25%
				W 24 (licensed dose)	PASI50: 81% PASI75: 47%
				W 48 (licensed dose)	PASI50: 82% PASI75: 54%
				W 72 (licensed dose)	PASI50: 87% PASI75: 52%
Esposito (31), 2012 ($n=61$)	Retrosp.[c]	Psoriasis patients with psoriatic arthritis: Etanercept 50 mg BIW SC. Patients with only psoriasis: Etanercept 50 mg BIW, followed by 25 mg BIW SC.	PASI50 PASI75 MPD	W 12 (licensed dose)	PASI50: 82% PASI75: 54.1% MPD: 73.3%
				W 24	PASI50: 90.2% PASI75: 78.7% MPD: 85.9%
				W 52	PASI50: 90.2% PASI75: 83.6% MPD: 87.9%
				W 104	PASI50: 91.8% PASI75: 86.9% MPD: 88.4%
				W 156	PASI50: 91.8% PASI75: 83.6% MPD: 86.9%
van Lümig (32), 2012 ($n=152$[a]) ($n=158$ TE)	Prosp.	Etanercept 50 mg BIW SC or 25 mg BIW SC (W0–12). Thereafter dosage according to the physician.	PASI50 PASI75 PASI90	W 12	PASI50: 65.6% PASI75: 23.6% PASI90: 5.1%
				W 24	PASI50: 69.7% PASI75: 38.1% PASI90: 14.9%
				W 48	PASI75: 36.6%
				W 108	PASI75: 40.8%
				W 156	PASI75: 50%
				W 204	PASI75: 59.4%
				W 264	PASI75: 60%
Puig (33), 2012 ($n=444$[a])	Prosp.	Etanercept 50 mg BIW SC (W0 –12) or 50 mg once W or 25 mg BIW (W0–12). After 12 W patients reaching a PASI50 could continue treatment. After 6 months the decision was made to treat patients continuously or intermittently.	PASI50 PASI75 PASI90 MPD MBSAD MPhGAD	W 12 Overall	PASI50: 88.4% PASI75: 63.9% PASI90: 37.8% MPD: 69.6% MBSAD: 66.4% MPhGAD: 62.5%
				W 12 Continuous regimen	PASI75: 63% PASI90: 34.8%
				W 12 Intermittent regimen	PASI75: 64% PASI90: 38.4%

				W 24	PASI50: 91.3% PASI75: 76.1% PASI90: 50.8% MPD: 81.4% MBSAD: 79.6% MPhGADR: 65.6%
				W 24 Continuous regimen W 24 Intermittent regimen	PASI75: 66.3% PASI90: 39.3% PASI75: 79% PASI90: 54.3%
				W 36	PASI50: 73.9 PASI75: 52.6% PASI90: 32.1% MPD: 63.4% MBSAD: 66.7% MPhGAD: 46.9%
				W 36 Continuous regimen W 36 Intermittent regimen	PASI75: 68.8% PASI90: 41.9% PASI75: 46.7% PASI90: 28.6%
				W 48	PASI50: 83.1% PASI75: 65.6% PASI90: 39.6% MPD: 74.6% MBSAD: 75.7% MPhGAD: 59.4%
				W 48 Continuous regimen W 48 Intermittent regimen	PASI75: 69.2% PASI90: 47.3% PhGA 0–1: 73.4% PASI75: 64.3% PASI90: 36.6% PhGA 0–1: 61.8%
Chiu (34), 2013 ($n=59^a$)	Retrosp.	Etanercept 25 mg BIW SC (W0–24). According to the response the dose was increased to 50 mg BIW SC (for 4–12W). Thereafter dose was reduced to 25 mg BIW SC.	PASI50 PASI75 PASI90 MPD	W 12 W 24	PASI50: 48% PASI75: 26% PASI90: 3% MPD: 47% PASI50: 59% PASI75: 37% PASI90: 14% MPD: 61%
van Lümig (35), 2013 ($n=131^a$) ($n=134$ TE)	Prosp.	Etanercept mean weakly dose 64.1 mg ± 14.0 mg.	PASI75 PASI90	W 24 W 48 W 108 W 156 W 204 W 264	PASI50: 67.9% PASI75: 38.1% PASI90: 14.9% PASI75: 36.6% PASI75: 40.8% PASI75: 50% PASI75: 59.4% PASI75: 60%
Menting (18), 2014 ($n=178$ TE^a)	Prosp.	Etanercept initiated by 50 mg BIW SC (W0 – 12) or 50 mg once W or 25 mg BIW. Thereafter, 50 mg BIW or dose frequency reduction (every 5, 7 or 10 days).	PASI75 PASI90 Naive PASI75 PASI90 Non-naive	W 12 W 52 W 12 W 52	PASI75: 32% PASI90: 9.9% PASI90: 13.3% PASI75: 12% PASI90: 4% PASI90: 13%
Infliximab					
Kalb (41), 2005 ($n=52^a$)	Retrosp.	Infliximab 5 mg/kg IV. W 0, 2, 6 and every 8 W.	PhGA 0 PhGA 1	W 14 (licensed dose)	PhGA 0: 38.5% PhGA 1: 50%
Gisondi (40), 2008 ($n=40$)	Retrosp.	Infliximab 5 mg/kg W 0, 2, 6 and every 8 W.	MPD	W 24 (licensed dose)	MPD: 88.8%
Gisondi (36), 2013 ($n=83$)	Prosp.	Infliximab 5 mg/kg W 0, 2, 6 and every 8 W.	PASI50 PASI75 MPD	W 4 (licensed dose) W 28 (licensed dose)	PASI75: 32% PR: 64% PASI50: 96% PASI75: 69% MPD: 85%
Menting (18), 2014 ($n=40$ TE^a)	Prosp.	Infliximab ± 5 mg/kg W 0, 2, 6 and every 8 W.	PASI75 PASI90 Naive	W 12 W 52	PASI75: 53% PASI90: 35.3% PASI90: 18.2%

			PASI75	W 12	PASI75: 38%
			PASI90		PASI90: 12%
			Non-naive	W 52	PASI90: 14%
Ustekinumab					
Clemmensen (37), 2011 (n=71)	Prosp.	Ustekinumab 45 or 90 mg (W 0, 4, and every 12 W).[e]	PASI75	W 16 (licensed dose)	PASI75: 80%
Laws (38), 2012 (n=129[a])	Retrosp.	Ustekinumab 45 or 90 mg (W 0, 4 and every 12 W.[e]	PASI50	W 16 (licensed dose)	PASI50: 82.7%
			PASI75		PASI75: 63%
			PASI90		PASI90: 29.1%
				W 24 (licensed dose)	PASI75: 66.7%
				W 48 (licensed dose)	PASI75: 65.5%
Ruiz Salas (39), 2012 (n=36[a])	Retrosp.	Ustekinumab 45 mg (W 0, 4 and every 8–12 W).[e]	PASI50	W 12	PASI50: 89.6%
			PASI75		PASI75: 79.3%
			PASI90		PASI90: 65.5%
			MPD		PR: 80.7%
				W 24	PASI50: 89.6%
					PASI75: 79.3%
					PASI90: 75.9%
					MPD: 80.9%
				W 36	PASI50: 89.6%
					PASI75: 89.6%
					PASI90: 75.9%
					MPD: 89.3%
		Ustekinumab 90 mg (W 0, 4 and every 8–12 W).	PASI50	W 12	PASI50: 85.7%
			PASI75		PASI75: 57.1%
			PASI90		PASI90: 28.5%
			MPD		MPD: 75.6%
				W 24	PASI50: 57.1%
					PASI75: 28.5%
					PASI90: 14.2%
					MPD: 48.2%
				W 36	PASI50: 85.7%
					PASI75: 71.4%
					PASI90: 54.1%
					MPD: 80%
		Ustekinumab both groups [45 and 90 mg] (W 0, 4 and every 8–12 W).	PASI50	W 12	PASI50: 91.7%
			PASI75		PASI75: 75%
			PASI90		PASI90: 58.3%
			MPD		MPD: 79.5%
				W 24	PASI50: 83.3%
					PASI75: 69.4%
					PASI90: 63.9%
					MPD: 71.9%
				W 36	PASI50: 88.8%
					PASI75: 71.4%
					PASI90: 57.1%
					MPD: 86.8%
Gisondi (36), 2013 (n=79)	Prosp.	Ustekinumab 45 or 90 mg (W 0, 4 and every 12 W).	PASI50	W 4 (licensed dose)	PASI75: 28%
			PASI75		MPD: 82%
		Dosing is weight dependent. Individuals weight (≤100 kg= ustekinumab 45mg; >100kg= 90 mg).	MPD	W 28 (licensed dose)	PASI50: 82%
					PASI75: 58%
					MPD: 60%
Acitretin					
Piaserico (42), 2014 (n=62)	Retrosp.	Acitretin mean 0.38 mg/kg/day.	PASI75	W 12	PASI75: 27%
Fumarates					
Carboni (43), 2004 (n=40)	Prosp.	Fumarates 30–360 mg/day. By remission doses were gradually reduced.	MPD	W 4	MPD: 39.6%
				W 12	MPD: 63%
				W 24	MPD: 80%
Inzinger (44), 2013 (n=272)	Retrosp.	Fumarates 30–720 mg/day.	PASI50	W 12	PASI50: 76%
			PASI75		PASI75: 47%
			PASI90		PASI90: 9%
			PASI100		PASI100: 1%
				W 24	PASI50: 82%
					PASI75: 63%
					PASI90: 27%
					PASI100: 5%

				W 48	PASI50: 90% PASI75: 76% PASI90: 34% PASI100: 12%
Cyclosporine					
Piaserico 42), 2014 (*n*=36)	Retrosp.	Cyclosporine mean 3.5 mg/kg/day.	PASI75	W 12	PASI75: 46%
Methotrexate					
Gisondi (40), 2008 (*n*=43)	Retrosp.	Methotrexate 15 mg/week IM.	MPD	W 24	MPD: 47.6%
Inzinger (44), 2013 (*n*=72)	Retrosp.	Methotrexate 10 mg/week SC increased to 20 mg/week SC.	PASI50 PASI75 PASI90 PASI100	W12	PASI50: 67% PASI75: 40% PASI90: 12% PASI100: 10%
				W 24	PASI50: 76% PASI75: 62% PASI90: 28% PASI100: 10%
				W 48	PASI50: 87.5% PASI75: 81% PASI90: 44% PASI100: 19%
Piaserico (42), 2014 (*n*=74)	Retrosp.	Methotrexate mean 11.7 mg/week.	PASI75	W 12	PASI75: 49%

[a]Additional conventional systemic therapies. [b]Patient switched from etanercept. [c]Patients with psoriasis with or without psoriatic arthritis. [d]Patients switching from efalizumab. [e]Dosing is weight dependent. Individuals weight (≤100 kg= ustekinumab 45 mg; >100 kg= 90 mg).

Retrosp.: retrospective; Prosp.: prospective; BIW: biweekly; BSA: body surface area; MBSAD: mean BSA decrease; EOW: every other week; IM: intramuscular; IV: intravenous; PASI: Psoriasis Area and Severity Index; MPD: mean PASI decrease; PhGA: Physician Global Assessment; MPhGAD: mean PhGA decrease; SC: subcutaneous; TE: treatment episode.